Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Dec 15:10:4073-4078.
doi: 10.2147/DDDT.S117080. eCollection 2016.

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes

Ali T Taher  1 , John B Porter  2 , Antonis Kattamis  3 , Vip Viprakasit  4 , M Domenica Cappellini  5
Affiliations
Comment

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes

Ali T Taher et al. Drug Des Devel Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

ATT reports receiving research funding and honoraria from Novartis. JBP reports consultancy, receiving research grant funding and honoraria from Novartis, consultancy and honoraria from Shire, and consultancy for Celgene. JBP is supported by the NIHR University College London Hospitals Biomedical Research Centre (BRC). AK reports participation in advisory boards and educational forums sponsored by Novartis and Apopharma and receiving research funding from Novartis. VV received research grant support and lecture fees from Novartis, Genzyme-Sanofi, Sebia, and Roche Diagnostics and research grant support from Shire, Sideris and Faculty of Medicine, Siriraj Hospital, Thailand. MDC reports receiving honoraria from Novartis, Genzyme, and Celgene. The authors report no other conflicts of interest in this work.

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther. 2016;10:465–481. - PMC - PubMed
    1. Taher AT, Porter J, Viprakasit V, et al. Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120(5):970–977. - PubMed
    1. Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol. 2013;92(11):1485–1493. - PMC - PubMed
    1. Novartis Pharmaceuticals [webpage on the Internet] EXJADE® (deferasirox) US Prescribing Information. 2015. [Accessed August 31, 2016]. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf.
    1. Nick H, Wong A, Acklin P, et al. ICL670A: preclinical profile. Adv Exp Med Biol. 2002;509:185–203. - PubMed